Navigation Links
CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
Date:9/3/2014

MONMOUTH JUNCTION, N.J., Sept. 3, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO) announced that Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the Rodman & Renshaw Annual Global Investment Conference (sponsored by H.C. Wainwright & Co) taking place on September 8-10th in New York City.   CytoSorbents is a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat patients with life-threatening inflammatory conditions in the intensive care unit in nineteen countries worldwide.

Conference Presentation Details:
Where:  New York Palace Hotel, 455 Madison Avenue, New York, NY 10022
When:  Tuesday, September 9th at 2:05 PM
Room:   Kennedy II Salon (4th Floor)
Webcast:  http://wsw.com/webcast/rrshq24/ctso
Conference Website:  Rodman and Renshaw 16th Annual Global Investment Conference

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to try to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO


'/>"/>
SOURCE CytoSorbents Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. CytoSorbents Records Another Solid Quarter of Growth in Q2 2014
2. CytoSorbents Expands Distribution to Taiwan with Hemoscien Corporation
3. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
4. Inovio to Present at Upcoming Investor Conferences
5. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
6. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
7. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
8. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
9. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
10. Volcano Corporation Presentation At Morgan Stanley Conference To Be Webcast
11. Hologic to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National ... encouraging people all over the United States to thank a nurse who's made a ... will donate $5 to the American Red Cross of San Diego/Imperial Counties (up to ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group ... today announced a new collaboration with Imerman Angels to expand outreach and ... the world. , “Imerman Angels provides an emotional lifeline to patients and families facing ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 ... and up 27 percent since 2012. , The results of the 2015 ASDS Survey ... increase in skin cancer treatments and the growing popularity of soft-tissue fillers and body ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Liposuction specialist Marcia ... Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s ... chosen to address the conference about her unique specialization in treating Lipedema. Dr. Byrd ...
Breaking Medicine News(10 mins):